Table 1

Clinical samples considered by this study with indication of the tumour percentage present in the relative formalin-fixed and paraffin-embedded material and in the targeted genes

Cancer typeSample numberTumour, %Hot spot mutations
CRC*1530%–90%; mean=40%KRAS, NRAS, BRAF, PIK3CA
Lung (NSCLC)1620%–70%; mean=30%KRAS, EGFR, ERBB2, PIK3CA
Melanoma830%–90%; mean=40%BRAF, PIK3CA
GIST860%–90%; mean=85%KIT, PDGFRA
Gastric carcinoma360%; 70%PIK3CA, KRAS
  • CRC, colorectal cancer; GIST, gastrointestinal stromal tumour; NSCLC, non-small cell lung cancer.